Cytiva/Cellular OriginsATMPsCellular Origines partners with Johnson ...British gene and cell therapy manufacturing specialist Cellular Origins Ltd has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous … more ➔
adobe stock photo - JR-50Cellular agricultureRapid progress in cultivated meatCultivated meat is expected to reach price parity with conventional meat sooner than previously forecast, according to a new analysis by technology foresight specialist GetFocus. more ➔
© MabionContract ManufacturingMabion launches €500,000 services contes... Lodz-based CDMO Mabion SA has launched a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of recombinant protein-based cancer therapies. … more ➔
AFYREN SABioeconomyFrench Afyren starts production of bio-aci...AFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill … more ➔
GEACellular agricultureGEA to open food biotech pilot-scale facil...GEA has launched its second Food Application and Technology Center (ATC) globally in the US, to target the largest consumer market for cellular agriculture. The facility features advanced bioreactors … more ➔
Max-Planck SocietyObesityThe smell of food makes you feel fullLose weight without expensive obesity pills? The discovery of a direct link between olfactory receptors and areas of the brain that signal satiety makes this seem possible, initially in mice. more ➔
adobe stock - trinsetFinancingSpliceBio SL secures US$135m in Series B f...SpliceBio SL has baged US$135m in a Series B financing co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors The Barcelona-based … more ➔
adobe stock.com - EtiAmmos FinancingMosanna Therapeutics bags $80m in Series A...Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118. more ➔
BIO-CATGene and cell therapiesSpanish BIO-CAT cluster starts new ATMP ac...The Spanish BIO-CAT cluster has launched a new accelerator called ATMP Catalyst, which will support six preclinical gene and cell therapy projects per year in each of three annual calls to support translation … more ➔
Frederick BernasBioeconomyBig deal: Amphistar goes transatlanticBelgian micriobial fermentation specialist AmphiStar NV has partnered with US plant-based ingredient heavyweight Kensing to market its biosurfactants in the US, using locally-produced feedstocks. Amphistar’s … more ➔